Cerivastatin-induced rhabdomyolysis: 11 case reports

被引：11

作者：

Ravnan, SL

Locke, C

Yee, WP

Haase, K

机构：

[1] Univ Pacific, Thomas J Long Sch Pharm & Hlth Sci, Stockton, CA 95211 USA

[2] St Josephs Med Ctr, Stockton, CA USA

来源：

PHARMACOTHERAPY | 2002年 / 22卷 / 04期

关键词：

D O I：

10.1592/phco.22.7.533.33674

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are a frequently prescribed class of drugs that are generally well tolerated by most patients. A rare, yet serious side effect associated with these drugs is rhabdomyolysis. Although all HMG-CoA reductase inhibitors can cause this adverse effect, prevalence may differ among specific agents. Over a 16-month period, in three hospitals, 11 patients experienced cerivastatin-induced rhabdomyolysis, but no cases of rhabdomyolysis associated with any other HMG-CoA reductase inhibitors were reported.

引用

页码：533 / 537

页数：5

共 41 条

[1]

Åberg F, 1998, EUR J CLIN INVEST, V28, P235

[2] Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil [J].

Alexandridis, G ;

Pappas, GA ;

Elisaf, MS .

AMERICAN JOURNAL OF MEDICINE, 2000, 109 (03) :261-262

[3] Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia [J].

Athyros, VG ;

Papageorgiou, AA ;

Hatzikonstandinou, HA ;

Didangelos, TP ;

Carina, MV ;

Kranitsas, DF ;

Kontopoulos, AG .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (05) :608-613

[4] Plasma concentrations of active simvastatin acid are increased by gemfibrozil [J].

Backman, JT ;

Kyrklund, C ;

Kivistö, KT ;

Wang, JS ;

Neuvonen, PJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :122-129

[5]

*BAY PHARM, 2001, BAYC CER PACK INS

[6]

*BAY PHARM, 1999, DAT FIL

[7] Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil [J].

Bermingham, RP ;

Whitsitt, TB ;

Smart, ML ;

Nowak, DP ;

Scalley, RD .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (05) :461-464

[8]

*BRIST SQUIBB, PRAV PRAV PACK INS

[9]

BURNHAM TH, 2001, DRUG FACTS COMPARISO, pA536

[10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

← 1 2 3 4 5 →